Results 81 to 90 of about 5,801 (166)

Molnupiravir is effective against hepatitis E virus infection in an animal model. [PDF]

Hepatol Commun
Wu S, Chew NF, Ma X, Situ J, Shun EH, Li C, Ip JD, Ho SS, Zhang AJ, Tsoi JY, Chan WM, Ma W, Liang Y, Mao W, Chen KWY, Yin F, To KK, Yuan S, Chan JF, Zhu L, Huang Y, Sridhar S.   +21 more
europepmc   +1 more source

<i>Boesenbergia rotunda</i>-Derived Phytochemicals as Potent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): Insights From Molecular Docking and Dynamic Simulation. [PDF]

Scientifica (Cairo)
Khan DA, Sheikh MA, Imon RR, Imtiaz M, Ahmed S, Gharami H, Labana RV, Jimoh TO, Gaurav A, Pereira ML, Nawaz M, Dungca JZ, Hasan MN, Ghosh M, Nissapatorn V.   +14 more
europepmc   +1 more source

Bio-inspired chemometric methods for simultaneous UV spectrophotometric determination of molnupiravir, nirmatrelvir, and favipiravir in pharmaceutical formulations and environmental samples. [PDF]

Sci Rep
Abdelzaher AM, Al Kamaly O, Rahman MAA.
europepmc   +1 more source

Molnupiravir Treatment Associated With Clearance of Cache Valley Virus From Cerebrospinal Fluid in an Immunocompromised Child With Meningoencephalitis. [PDF]

Open Forum Infect Dis
Byrd DS, Ananth A, McDonald C, Atkinson TP, Chiu CY, Kimberlin DW, Marcus L.   +6 more
europepmc   +1 more source

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection. [PDF]

J Antimicrob Chemother
Khoo SH, FitzGerald R, Edwards CJ, Ahmad S, Saunders G, Else LJ, Shaw V, Mozgunov P, Northey J, Dickinson L, Knox E, Buadi A, Hale C, Reynolds HE, Middleton C, Bullock K, Walker L, Walker L, Tetlow M, Lyon R, Gibney J, Amara A, Greenhalf W, Burdon A, Dixon J, Jaki T, Chiong J, Lalloo DG, Owen A, Jacobs M, Fletcher T, Griffiths G, AGILE CST-8 study group .   +32 more
europepmc   +1 more source

Uridine cytidine kinases govern molnupiravir bioactivation and anti-SARS-CoV-2 activity. [PDF]

PLoS Pathog
Shu H, Ludäscher JM, Sharma S, Alam S, Frank L, Hutchinson ES, Tampere M, Lévêque C, van Kuilenburg ABP, Valerie NCK, Altun M, Chabes A, Stenmark P, Rudd SG, Zhang SM.   +14 more
europepmc   +1 more source

Antivirals Targeting Coronavirus RNA-Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID-19 Clinical Trials. [PDF]

Microb Biotechnol
Brüssow H.
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID diabetes risk among an older adult cohort: a target trial emulation study. [PDF]

BMC Med
Guo Z, Wei Y, Yang A, Wong CKH, Xiong X, Wang K, Lin G, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Zhao S, Mok CKP, Hui DSC, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source

Novel green UPLC method with life cycle assessment for determination of favipiravir and molnupiravir drugs and environmental water samples. [PDF]

Sci Rep
Kelani KM, Elsherbiny MS, Eid SM, Ghany MFA, Abbas MM.   +4 more
europepmc   +1 more source

Update on Treatment of Feline Infectious Peritonitis: European Advisory Board on Cat Diseases (ABCD) Guidelines. [PDF]

Viruses
Tasker S, Spiri AM, Hartmann K, Addie DD, Belák S, Bergmann M, Egberink H, Frymus T, Hofmann-Lehmann R, Marsilio F, Pennisi MG, Thiry E, Truyen U, Boucraut-Baralon C, Möstl K, Hosie MJ.   +15 more
europepmc   +1 more source